Alemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study.

Alemtuzumab and sirolimus in renal transplantation: six-year results of a single-arm prospective pilot study.

mTOR inhibitors avoid calcineurin nephrotoxicity, but sirolimus de novo is associated with unacceptable side effects and higher rejection rates. We have investigated a modified strategy: alemtuzumab induction with tacrolimus and mycophenolate maintenance, switching from tacrolimus to sirolimus at 6...

Detaylı Bibliyografya
Asıl Yazarlar:	Sutherland, A, Akhtar, M, Zilvetti, M, Brockmann, J, Ruse, S, Fuggle, S, Sinha, S, Harden, P, Friend, P
Materyal Türü:	Conference item
Baskı/Yayın Bilgisi:	2014

Benzer Materyaller

Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression.
Yazar:: Flechner, S, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression.
Yazar:: Trzonkowski, P, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

ALEMTUZUMAB INDUCTION IN PANCREAS TRANSPLANTATION
Yazar:: Muthusamy, A, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Systematic reviews of alemtuzumab in renal transplantation.
Yazar:: O'Callaghan, J, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Systematic reviews of alemtuzumab in renal transplantation
Yazar:: O'Callaghan, J, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Alemtuzumab induction and steroid free immunosupprssion in pancreas transplantation.
Yazar:: Muthusamy, A, ve diğerleri
Baskı/Yayın Bilgisi: (2007)

Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation.
Yazar:: Muthusamy, A, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Results of a Large Randomized Controlled Trial of Alemtuzumab-Versus Basiliximab-Based Induction Therapy in Kidney Transplantation
Yazar:: Haynes, R, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Results of a Large Randomized Controlled Trial of Alemtuzumab-Versus Basiliximab-Based Induction Therapy in Kidney Transplantation
Yazar:: Haynes, R, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Steroid-free immunosuppression in pancreas transplantation using Alemtuzumab induction
Yazar:: Muthusamy, A, ve diğerleri
Baskı/Yayın Bilgisi: (2007)

Effect of alemtuzumab or basiliximab induction therapy on graft function and survival of kidneys from donors after cardiac death.
Yazar:: Plata-Munoz, J, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Campath 1H (alemtuzumab) in renal transplantation: 5-year comparative follow up.
Yazar:: Watson, C, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Elective conversion to sirolimus vs. continued tacrolimus in kidney transplantation (the 3c study): Results of a randomized trial
Yazar:: Haynes, R, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Late treatment with autologous expanded regulatory T-cell therapy after alemtuzumab induction is safe and facilitates immunosuppression minimization in living donor renal transplantation
Yazar:: Brook, MO, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
Yazar:: Haynes, R, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Alemtuzumab: right drug, right dose?
Yazar:: Haynes, R, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Liver transplantation from non-heart-beating donors: current status and future prospects.
Yazar:: Reddy, S, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

The evolving role of alemtuzumab (Campath-1H) in renal transplantation
Yazar:: Phuong-Thu T Pham, ve diğerleri
Baskı/Yayın Bilgisi: (2008-12-01)

Risk factors for delayed graft function defined as need for dialysis or failure of creatinine to fall by 10% in the first 24 hours after transplant.
Yazar:: Stratopoulos, C, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype.
Yazar:: Carroll, R, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Application of operational tolerance signatures are limited by variability and type of immunosuppression in renal transplant recipients: A cross-sectional study.
Yazar:: Bottomley, M, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

PRE-TRANSPLANT ASSESSMENT FOR LIVING DONOR RENAL TRANSPLANTATION: EVALUATION OF THE XM-ONE ASSAY
Yazar:: Procter, J, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
Yazar:: Clatworthy, MR, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Risk analysis for deterioration of renal function after pancreas alone transplant.
Yazar:: Chatzizacharias, N, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Terapia de indução com alentuzumabe em receptores de transplante renal Alemtuzumab induction in kidney transplant recipients
Yazar:: Edison Luiz Mandia Sampaio, ve diğerleri
Baskı/Yayın Bilgisi: (2010-03-01)

Reversible sirolimus-induced pulmonary alveolar proteinosis in a renal transplant patient
Yazar:: David Eugenio Hinojosa-González, ve diğerleri
Baskı/Yayın Bilgisi: (2020-01-01)

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
Yazar:: Watson, C, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

Our Unique Experience with Low-Dose Alemtuzumab as an Induction Agent for Renal Transplantation: A Case Series
Yazar:: Cherin Josi, ve diğerleri
Baskı/Yayın Bilgisi: (2024-12-01)

Normothermic presevation and transplantation of heart-beating-donor porcine livers.
Yazar:: Reddy, S, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

Evaluation of the XM-ONE assay and the role of endothelial cell antibodies in recipients of living donor renal transplants
Yazar:: Procter, J, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Conversion to Combined Therapy with Sirolimus and Mycophenolate Mofetil Improved Renal Function in Stable Renal Transplant Recipients
Yazar:: Meng-Kun Tsai, ve diğerleri
Baskı/Yayın Bilgisi: (2007-05-01)

Impact of immunosuppression on the incidence of early subclinical renal allograft rejection: implications for protocol biopsy policy.
Yazar:: Roberts, I, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Prevalence of nonmalignant cutaneous disease in renal transplant recipients
Yazar:: Lally, A, ve diğerleri
Baskı/Yayın Bilgisi: (2006)

Evaluation of the XM-ONE (R) assay and the role of endothelial cell antibodies in recipients of living donor renal transplants
Yazar:: Procter, J, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis.
Yazar:: Morgan, R, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients
Yazar:: Joel D. Morrisett, ve diğerleri
Baskı/Yayın Bilgisi: (2002-08-01)

Update on the long-term complications of renal transplantation.
Yazar:: Bottomley, M, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Expanded criteria donors in pancreas transplantation: The Oxford experience
Yazar:: Muthusamy, A, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Proteinuria and baseline renal function predict mortality and renal outcomes after sirolimus therapy in liver transplantation recipients
Yazar:: Lung-Chih Li, ve diğerleri
Baskı/Yayın Bilgisi: (2017-04-01)

Alemtuzumab Plus Cyclosporine Treatment of the Autoimmune Hemolytic Anemia in an Adult Bowel Transplant
Yazar:: A. Lauro, ve diğerleri
Baskı/Yayın Bilgisi: (2014-01-01)